Decreasing Butyricimonas genus

For updated information see Microbiome Prescription Data


PubMed Data

There are 25+ studies on PubMed.

  • Body Impact
    • ” Results indicated fecal Ruminococcus and Butyricimonas predicted brain N-acetylaspartate (NAA). Analysis of serum biomarkers indicated Ruminococcus independently predicted serum serotonin and cortisol. ” [2017]
    • “A positive correlation was found between Butyricimonas and mean arterial pressure (MAP).” [2016]  See this page to compute your MAP
  • Disease:
    • ” multiple sclerosis ..decreases in Butyricimonas” [2016]
    • Butyricimonas, and Clostridium XlVb, which were most abundant in the Active major depressive disorder ” [2016]
  • Antibiotics:
    • “resistant to vancomycin (5 μg), kanamycin (1 mg) and colistin sulphate (10 μg),….The results showed sensitivity to ampicillin, sulbactam-ampicillin, amoxicillin-clavulanic acid, piperacillin-tazobactam, imipenem, meropenem, clindamycin and metronidazole.” [2015]
    • “Susceptibility testing of the isolate revealed penicillin and ceftriaxone resistance, but susceptibility to metronidazole. ” [2016]
  • Probiotics:
    • Butyricimonas, a butyrate producer (23), and Prevotella, a propionate producer (24), increased the relative abundance more dramatically in the ProPre group… composed of Lactobacillus rhamnosus GG (LGG), viable Escherichia coli Nissle 1917 (EcN), and heat-inactivated VSL#3 (1:1:1).  ” [2016]
    • Bifidobacterium animalis subsp. lactis B-12®) and Lactobacillus rhamnosus (LGG®) … [increased]” [2017]
    • L. salivarius UCC118 expressing bacteriocin … reduced” [2012]
    • Clostridium butyricum  … increases” [2015]

Bottom Line


  • Bifidobacterium animalis subsp.  lactis  B-12®) [See PDF where it was found to increase it 3 fold]
  • Clostridium butyricum (i.e. Miyarisan) probiotics


  • E.Coli Probioitics
  • Lactobacillus salivarius